Pancreatic ductal adenocarcinoma (PDAC) is relatively uncommon yet remains one of the most lethal cancers worldwide.
Nonlinear Mixed-Effects Modeling to Characterize the Pharmacokinetics of a Novel Mithramycin Analogue for Ewing Sarcoma in Mice
To develop a pharmacokinetic model for a novel mithramycin analogue, MTMSA-Trp, in mice and characterize dose-dependent disposition to support future pharmacokinetic-pharmacodynamic (PK/PD) and exposure-e cacy analyses.
Piperazine-Thiourea Hybrids as Novel Antiplatelet Agents Targeting COX-1: Synthesis, in Vitro, and in Silico Evaluation
Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, reinforcing the need for safer and more effective antiplatelet therapies.
Pharmacokinetic Evaluation of Etoricoxib 120mg Tablets in Healthy Human Pakistani Volunteers: In-Vivo In-Silico Bridging for Bioequivalence
Etoricoxib is a selective cyclooxygenase-2 inhibitor widely used for the treatment of pain and inflammatory conditions.
In Silico Designing of Palbociclib Loaded Plga Long-Acting Intramuscular Injection for Palliative Therapy of HR+/HER2− Metastatic Breast Cancer
Palbociclib (PBB) is an oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved for the treatment of HR+/HER2− breast cancer.
Comparison of Population Pharmacokinetic Platforms, Monolix and Phoenix for Cephalexin in Infants
Cephalexin is a commonly used antibiotic for pediatric populations, however, data to guide effective oral dosing in young infants are limited.
Population Pharmacokinetics of Encorafenib and Binimetinib in Real-World Patients with BRAFV600E/K-Mutant Metastatic Melanoma
Encorafenib and binimetinib pharmacokinetic (PK) studies in real-world cancer patients remain scarce.
Integrating Systemic Toxicity and Toxicokinetic Data to Inform the Need for Subchronic Dog Studies in Human Health Safety Assessments of Agrochemicals
Regulatory testing for agrochemicals has traditionally included a 90-day toxicity study in a non-rodent species, usually the dog.
Prediction of the Lurasidone–Posaconazole Drug–Drug Interaction Using Physiologically Based Pharmacokinetic Modeling
Lurasidone is an atypical antipsychotic drug that metabolized by cytochrome P4503A4 (CYP3A4). Posaconazole is a triazole antifungal agent known to inhibit CYP3A4activity.
Metabolic Profiling and Detoxification of Eupalinolide A and B in Human Liver Microsomal Systems
Eupalinolide A (EA, Z-configuration) and Eupalinolide B (EB, E-configuration) are cis-trans isomeric sesquiterpenoid monomers isolated from Eupatorium lindleyanum DC. (Asteraceae).
Automated Concentration-QT data preparation, model selection and reporting in R
Since the publication of the ICH E14 guidance in 2015, QT interval prolongation as-sessment can be carried out with a concentration-QTc modeling approach as part of single- or mul-tiple- dose escalation studies, instead of conducting a thorough QT/QTc study.
Pharmacokinetic Studies and Synergistic Antitumor Effects of Cannabichromene and Cannabidiol in Drug-Resistant Breast Cancers
Triple-negative breast cancer (TNBC) is highly aggressive with limited treatment options, and resistance to doxorubicin (DOX) further compromises outcomes.
High-Throughput Physiologically Based Pharmacokinetic Model for Rodent Pharmacokinetics Prediction Using Machine Learning-Predicted Inputs and a Large In Vivo Pharmacokinetics Data Set
Accurate prediction of the pharmacokinetic (PK) properties of small-molecule drug candidates is a critical aspect of pharmaceutical research.
Design, Synthesis, and Pharmacological Evaluation of Metabolically Stable Apelin Receptor Antagonists with Improved In Vivo Exposure and Efficacy in Ovarian Cancer
The apelin receptor (APJ) has emerged as a potential novel therapeutic target in cancer due to its role in regulating cell proliferation, angiogenesis, and metastasis.
Investigating the SNAC-To-Drug Ratio for the Oral Absorption of Cyanocobalamin in Rats
The oral route of administration continues to be the preferred and most convenient method for drug delivery among both patients and healthcare professionals.
Novel Descriptors and Models for More Accurate ADME Predictions of Beyond Rule of Five Molecules
This study addresses the critical need for improved physicochemical descriptors and predictive models tailored to beyond Rule of Five (bRo5) compounds, including PROTACs and cyclic peptides. B
Development of a Pregnancy-Specific Physiologically Based Pharmacokinetics (PBPK) Model for Aspirin
Aspirin is one of the most commonly used medications in pregnancy, particularly for the prevention of hypertensive disorders.
Quantitative Systems Toxicology Modeling with DILIsym to Support Phase 3 Dose Selection for Fezolinetant
Fezolinetant is a first-in-class, selective, non-hormonal, neurokinin 3 receptor antagonist that is approved for the treatment of moderate to severe vasomotor symptoms due to menopause.
Fabrication of Second-Generation Acalabrutinib Nanocrystals by Employing the Nano-Edge Method for Improving the Physico-Chemical Properties and Forecasting their In-Silico Pharmacokinetic Behaviour
Acalabrutinib (ACL) is approved by the USFDA and classified as a BCS class II drug, primarily used for treating chronic lymphocytic leukaemia.
Unveiling Anticancer Potential of Imidazo-Pyridine/Pyrazine-Fused bicyclic Heterocycles: Insights From in silico and in vitro Studies
Cancer is a significant global health challenge and the second leading cause of death worldwide, responsible for millions of fatalities annually.